Lite Strategy (LITS) Q1 2026 earnings summary

Executive summary

• Transitioned from oncology drug development to a dual focus on pre-clinical programs and a digital asset treasury strategy centered on Litecoin (LTC) as a primary reserve asset.

• Closed a $100 million PIPE in July 2025, issuing common stock and pre-funded warrants, and fully deployed proceeds into LTC by August 2025.

• Announced a $25 million share repurchase program in October 2025, shifting from LTC accumulation to active capital market operations.

Financial highlights

• Net loss of $3.6 million for the quarter ended September 30, 2025, compared to $8.0 million in the prior year period.

• Research and development expenses dropped 99.7% year-over-year to $10,000, reflecting the wind-down of clinical programs.

• General and administrative expenses decreased 40.3% to $3.1 million, offset by new asset management and advisory fees related to the digital asset strategy.

• $100 million invested in LTC, with a fair value of $99.4 million as of September 30, 2025.

• Cash and cash equivalents of $10.1 million at quarter-end.

• Net cash provided by financing activities was $96.6 million, primarily from PIPE and ATM equity offerings.

Outlook and guidance

• Sufficient liquidity, including digital assets, to fund operations for at least the next 12 months.

• Plans to conduct additional pre-clinical research and development in fiscal 2026.

• Potential expansion into LTC mining activities under ongoing digital asset strategy.